Young laboratory woman with testtubes

Recent News

August 2022

August 2022 aTen Therapeutics awarded £282k Innovate UK grant to develop new breast cancer treatment.

March 2020

aTen Therapeutics relocates to new offices at 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA.

August 2019

Ian Abercrombie appointed Chief Executive Officer at aTen Therapeutics.

aTen Therapeutics

An innovative biotechnology company based in Edinburgh, Scotland

We are developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Our technology has great potential to provide powerful new treatment options to extend and improve lives.

TENSINUMAB (ATN-E11)

Our lead candidate - a novel therapeutic human antibody that significantly inhibits tumour growth and prolongs survival in experimental models of cancer.

info@atentherapeutics.com

© aTen Therapeutics 2022. All rights reserved